Shopping Cart
Total:

$0.00

Items:

0

Checkout View Cart
Your cart is empty
Keep Shopping

First Therapy to Target Muscle Loss in Spinal Muscular Atrophy Gets FDA Approval



(MedPage Today) — The FDA approved apitegromab (Isembyld) injection to treat spinal muscular atrophy (SMA) in adults and pediatric patients ages 2 years and older who currently are receiving an SMN2-targeted treatment, the agency announced Friday…



Source link

0
Show Comments (0) Hide Comments (0)
0 0 votes
Article Rating
Subscribe
Notify of
guest
0 Comments
Oldest
Newest Most Voted
Inline Feedbacks
View all comments